Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jul 30:13:2301-2311.
doi: 10.2147/COPD.S163795. eCollection 2018.

COPD affects worker productivity and health care costs

Jeetvan G Patel  1 , Anna D Coutinho  2 , Orsolya E Lunacsek  2 , Anand A Dalal  3
Affiliations
Observational Study

COPD affects worker productivity and health care costs

Jeetvan G Patel et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Purpose: This study aimed to measure the true burden of COPD by calculating incremental direct and indirect costs. Direct medical resource use, productivity metrics, and COPD-specific resource use and costs were also evaluated.

Patients and methods: This was a retrospective, observational, matched cohort study using administrative claims data from the Truven Health MarketScan® Commercial Claims and Encounters and the Health and Productivity Management databases (2007-2010). Working-age (18-65 years) patients with COPD were identified as having at least one hospitalization or one emergency department visit or two outpatient visits. Patients in the non-COPD cohort did not have a diagnosis of COPD during the study period. Outcomes were evaluated in the first full calendar year after the year of identification (index).

Results: Of the 5,701 patients with COPD identified, 3.6% patients were frequent exacerbators (≥2), 10.4% patients were infrequent exacerbators (1), and 86% patients were non-exacerbators (0). When compared with the 17,103 patients without COPD, the incremental direct cost of COPD was estimated at $6,246/patient/year (95% confidence interval: $4,620, $8,623; P<0.001). Loss in productivity was significantly greater in patients with COPD, with an average of 5 more days/year of absence from work and incremental indirect costs from short-term disability of $641 (P<0.001). Direct costs for frequent exacerbators ($17,651/year) and infrequent exacerbators ($14,501/year) were significantly higher than those for non-exacerbators ($11,395, P<0.001).

Conclusion: Working-age patients with COPD incur statistically significantly higher direct and indirect costs and use more resources compared with those who do not have COPD.

Keywords: COPD; cost; employer; exacerbation; productivity; resource.

PubMed Disclaimer

Conflict of interest statement

Disclosure JGP and AAD were employees of GSK at the time of the study conduct. JGP is currently an employee of Amgen and owns stocks/shares. AAD is currently an employee of Novartis Pharmaceuticals and owns stocks/shares. ADC and OEL are employees of Xcenda, a health care consulting company contracted by GSK for the conduct of this study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Annual adjusteda direct and indirect costs between COPD and non-COPD cohorts. Notes: Sample evaluated – direct costs: COPD (n=5,701) and non-COPD (n=17,103) and short-term disability: COPD (n=5,514) and non-COPD (n=16,542). aAdjusted for comorbidities included in the CCI, including those associated with COPD. *P<0.001. Abbreviations: CCI, Charlson Comorbidity Index; USD, US dollar.
Figure 2
Figure 2
Annual adjusteda productivity metrics by exacerbator status. Notes: aAdjusted for comorbidities included in the CCI, including those associated with COPD. bP-value – compared with non-exacerbators. Abbreviation: CCI, Charlson Comorbidity Index.
Figure 3
Figure 3
Adjusted indirect costs per year by exacerbator status. Note: aP-value – compared with non-exacerbators. Abbreviation: USD, US dollar.
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2018. [Accessed April 27, 2018]. Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revi.... - PubMed
    1. National Heart Lung and Blood Institute Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung and Blood Diseases. 2009. [Accessed May 16, 2018]. Available from: https://ecopmc.files.wordpress.com/2012/04/2009_chart-book.pdf.
    1. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245. - PMC - PubMed
    1. Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014;9:289–300. - PMC - PubMed
    1. Report MC. Chronic Obstructive Pulmonary Disease (COPD): An Actuarial Analysis of Drug Therapy Treatment Patterns for a Commercially Insured Population. 2011. [Accessed June 21, 2013]. Available from: http://www.milliman.com/uploadedFiles/insight/research/health-rr/chronic....

Publication types